Market Opportunity PetDx offers a first-in-class canine multi-cancer early detection test (OncoK9) using NGS and proprietary bioinformatics, presenting a compelling entry point for veterinary clinics seeking advanced diagnostics and preventive care offerings.

Strategic Partners Existing collaboration with Petco and the clinical adoption by veterinary clinics indicate a channel-friendly path; leverage partnerships to expand clinic access, scale adoption, and co-market to pet owners.

Growth Signals Recent leadership change to a physician-executive team and Series B funding in 2021/2022 suggest a company poised for scale; identify opportunities to upsell adjacent genomic or liquid biopsy services as the platform matures.

Tech & Data NGS-based detection with proprietary analytics offers a differentiator; propose integrations with clinic management systems and data-sharing capabilities to streamline ordering, results delivery, and longitudinal pet health tracking.

Niche Differentiation Small team size relative to peers presents a need for scalable education and support; develop a targeted playbook for quick onboarding, training resources, and tiered support to accelerate adoption in veterinary networks.